Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2021

01-12-2021 | Insulins | Research

Combination therapy of flaxseed and hesperidin enhances the effectiveness of lifestyle modification in cardiovascular risk control in prediabetes: a randomized controlled trial

Authors: Zahra Yari, Zahra Naser-Nakhaee, Elahe Karimi‐Shahrbabak, Makan Cheraghpour, Mehdi Hedayati, Seyede Marjan Mohaghegh, Shahrzad Ommi, Azita Hekmatdoost

Published in: Diabetology & Metabolic Syndrome | Issue 1/2021

Login to get access

Abstract

Background

Regarding the increasing prevalence of cardiometabolic abnormalities, and its association with non-communicable chronic diseases, providing preventive and therapeutic strategies is a priority. A randomized placebo-controlled study was conducted to assess the effects of combination therapy of milled brown flaxseed and hesperidin during lifestyle intervention on controlling cardiovascular risk in prediabetes.

Methods

A total of forty-eight subjects were randomly assigned to receive lifestyle intervention plus combination therapy of brown flaxseed (30 g milled) and hesperidin (two 500 mg capsules) or lifestyle modification alone for 12 weeks. Changes from baseline in anthropometric measures, lipid profile and atherogenic indices, glucose homeostasis parameters, and inflammatory biomarkers was assessed as a primary end point.

Results

Anthropometric data comparison between the two groups showed a significant reduction in weight (p = 0.048). Waist circumference reduction was about twice that of the control group (− 6.75 cm vs − 3.57 cm), but this difference was not statistically significant. Comparison of blood pressure changes throughout the study indicated a greater reduction in blood pressure in the intervention group rather than control group (− 5.66 vs. − 1.56 mmHg, P = 0.049). Improvements of lipid profile and atherogenic indices, glucose homeostasis parameters, and inflammatory biomarkers in flaxseed-hesperidin group was significantly more than the control group after 12 weeks of intervention (p < 0.05).

Conclusion

Our results indicate that co-administration of flaxseed and hesperidin as an adjunct to lifestyle modification program is more effective than lifestyle modification alone in the metabolic abnormalities remission of prediabetic patients.
Trial registration: The trial was registered with ClinicalTrials.gov, number NCT03737422. Registered 11 November 2018. Retrospectively registered, https://​clinicaltrials.​gov/​ct2/​results?​cond=​&​term=​NCT03737422&​cntry=​&​state=​&​city=​&​dist=​.
Literature
1.
Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nature Rev Endocrinol. 2012;8(4):228–36.CrossRef
2.
Bansal N. Prediabetes diagnosis and treatment: a review. World J Diab. 2015;6(2):296.CrossRef
3.
Daniele G, Abdul-Ghani M, DeFronzo RA. What are the pharmacotherapy options for treating prediabetes? Expert Opin Pharmacother. 2014;15(14):2003–18.PubMedCrossRef
4.
Liu T. A Comparison of Biological, Physical, and Psychological Risk Factors forCardiovascular Disease In Overweight/Obese Individuals With and Without Prediabetes: Emory University; 2015.
5.
Lindström J, Peltonen M, Eriksson J, Ilanne-Parikka P, Aunola S, Keinänen-Kiukaanniemi S, et al. Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia. 2013;56(2):284–93.PubMedCrossRef
6.
7.
Agrawal YO, Sharma PK, Shrivastava B, Ojha S, Upadhya HM, Arya DS, et al. Hesperidin produces cardioprotective activity via PPAR-gamma pathway in ischemic heart disease model in diabetic rats. PLoS ONE. 2014;9(11):e111212.PubMedPubMedCentralCrossRef
8.
Cavia-Saiz M, Busto MD, Pilar-Izquierdo MC, Ortega N, Perez-Mateos M, Muñiz P. Antioxidant properties, radical scavenging activity and biomolecule protection capacity of flavonoid naringenin and its glycoside naringin: a comparative study. J Sci Food Agric. 2010;90(7):1238–44.PubMedCrossRef
9.
Poudyal H, Panchal SK, Diwan V, Brown L. Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action. Prog Lipid Res. 2011;50(4):372–87.PubMedCrossRef
10.
Oomah BD. Flaxseed as a functional food source. J Sci Food Agric. 2001;81(9):889–94.CrossRef
11.
Morris DH. Flax: A health and nutrition primer: Flax Council of Canada; 2007.
12.
Munir KM, Chandrasekaran S, Gao F, Quon MJ. Mechanisms for food polyphenols to ameliorate insulin resistance and endothelial dysfunction: therapeutic implications for diabetes and its cardiovascular complications. Am J Physiol Endocrinol Metab. 2013;305(6):E679.PubMedPubMedCentralCrossRef
13.
Jung UJ, Lee M-K, Jeong K-S, Choi M-S. The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J Nutri. 2004;134(10):2499–503.CrossRef
14.
Rhee Y, Brunt A. Flaxseed supplementation improved insulin resistance in obese glucose intolerant people: a randomized crossover design. Nutr J. 2011;10(1):44.PubMedPubMedCentralCrossRef
15.
Hutchins AM, Brown BD, Cunnane SC, Domitrovich SG, Adams ER, Bobowiec CE. Daily flaxseed consumption improves glycemic control in obese men and women with pre-diabetes: a randomized study. Nutri Res. 2013;33(5):367–75.CrossRef
16.
Homayouni F, Haidari F, Hedayati M, Zakerkish M, Ahmadi K. Hesperidin supplementation alleviates oxidative DNA damage and lipid peroxidation in type 2 diabetes: a randomized double-blind placebo-controlled clinical trial. Phytotherapy Res PTR. 2017;31(10):1539–45.CrossRef
17.
Kim JY, Jung KJ, Choi JS, Chung HY. Modulation of the age-related nuclear factor-κB (NF-κB) pathway by hesperetin. Aging Cell. 2006;5(5):401–11.PubMedCrossRef
18.
Sekgala MD, McHiza ZJ, Parker WA, Monyeki KD. Dietary Fiber Intake and Metabolic Syndrome Risk Factors among Young South African Adults. Nutrients. 2018;10(4).
19.
Chen JP, Chen GC, Wang XP, Qin L, Bai Y. Dietary Fiber and Metabolic Syndrome: A Meta-Analysis and Review of Related Mechanisms. Nutrients. 2017;10(1).
20.
Thakur G, Mitra A, Pal K, Rousseau D. Effect of flaxseed gum on reduction of blood glucose and cholesterol in type 2 diabetic patients. Int J Food Sci Nutr. 2009;60(sup6):126–36.PubMedCrossRef
21.
Barre D, Mizier-Barre K, Stelmach E, Hobson J, Griscti O, Rudiuk A, et al. Flaxseed lignan complex administration in older human type 2 diabetics manages central obesity and prothrombosis—an invitation to further investigation into polypharmacy reduction. Journal of nutrition and metabolism. 2012;2012.
22.
Cunnane SC, Ganguli S, Menard C, Liede AC, Hamadeh MJ, Chen Z-Y, et al. High α-linolenic acid flaxseed (Linum usitatissimum): some nutritional properties in humans. Br J Nutr. 1993;69(2):443–53.PubMedCrossRef
23.
Selvamuthukumaran M, Boobalan MS, Shi J. Bioactive Components in Citrus Fruits and Their Health Benefits. Phytochemicals in Citrus: Applications in Functional Foods. 2017.
24.
Rizza S, Muniyappa R, Iantorno M, Kim JA, Chen H, Pullikotil P, et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab. 2011;96(5):E782–92.PubMedPubMedCentralCrossRef
25.
Salden BN, Troost FJ, de Groot E, Stevens YR, Garcés-Rimón M, Possemiers S, et al. Randomized clinical trial on the efficacy of hesperidin 2S on validated cardiovascular biomarkers in healthy overweight individuals. Am J Clin Nutri. 2016;104(6):1523–33.CrossRef
26.
Constans J, Bennetau-Pelissero C, Martin J-F, Rock E, Mazur A, Bedel A, et al. Marked antioxidant effect of orange juice intake and its phytomicronutrients in a preliminary randomized cross-over trial on mild hypercholesterolemic men. Clin Nutr. 2015;34(6):1093–100.PubMedCrossRef
27.
Morand C, Dubray C, Milenkovic D, Lioger D, Martin JF, Scalbert A, et al. Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers. Am J Clin Nutri. 2011;93(1):73–80.CrossRef
28.
Rangel-Huerta OD, Aguilera CM, Martin MV, Soto MJ, Rico MC, Vallejo F, et al. Normal or high polyphenol concentration in orange juice affects antioxidant activity, blood pressure, and body weight in obese or overweight adults. J Nutri. 2015;145(8):1808–16.CrossRef
29.
Association AD. 2. Classification and diagnosis of diabetes. Diabetes care. 2017;40(Supplement 1):S11-S24.
30.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.PubMedCrossRef
31.
Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.CrossRefPubMed
32.
Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402–10.CrossRefPubMed
33.
Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem. 2004;50(7):1184–8.PubMedCrossRef
34.
Badeli H, Assadi F. Strategies to reduce pitfalls in measuring blood pressure. Int J Preventive Med. 2014;5(Suppl 1):S17.
35.
Miwa Y, Mitsuzumi H, Sunayama T, Yamada M, Okada K, Kubota M, et al. Glucosyl hesperidin lowers serum triglyceride level in hypertriglyceridemic subjects through the improvement of very low-density lipoprotein metabolic abnormality. J Nutr Sci Vitaminol. 2005;51(6):460–70.PubMedCrossRef
36.
Demonty I, Lin Y, Zebregs YE, Vermeer MA, van der Knaap HC, Jäkel M, et al. The citrus flavonoids hesperidin and naringin do not affect serum cholesterol in moderately hypercholesterolemic men and women–3. J Nutri. 2010;140(9):1615–20.CrossRef
37.
Rizza S, Muniyappa R, Iantorno M, Kim J, Chen H, Pullikotil P, et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab. 2011;96(5):E782-E92.CrossRef
38.
Assini JM, Mulvihill EE, Huff MW. Citrus flavonoids and lipid metabolism. Curr Opin Lipidol. 2013;24(1):34–40.PubMedCrossRef
39.
Soltanian N, Janghorbani M. Effect of flaxseed or psyllium vs. placebo on management of constipation, weight, glycemia, and lipids: A randomized trial in constipated patients with type 2 diabetes. Clinical nutrition ESPEN. 2019;29:41-8.
40.
Hasaniani N, Rahimlou M, Ramezani Ahmadi A, Mehdizadeh Khalifani A, Alizadeh M. The Effect of Flaxseed Enriched Yogurt on the Glycemic Status and Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus: randomized, Open-labeled. Controlled Study Clin Nutr Res. 2019;8(4):284–95.PubMedCrossRef
41.
Fukumitsu S, Aida K, Ueno N, Ozawa S, Takahashi Y, Kobori M. Flaxseed lignan attenuates high-fat diet-induced fat accumulation and induces adiponectin expression in mice. Br J Nutr. 2008;100(3):669–76.PubMedCrossRef
42.
Bloedon LT, Balikai S, Chittams J, Cunnane SC, Berlin JA, Rader DJ, et al. Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial. J Am Coll Nutr. 2008;27(1):65–74.PubMedCrossRef
43.
Mirmasoumi G, Fazilati M, Foroozanfard F, Vahedpoor Z, Mahmoodi S, Taghizadeh M, et al. The Effects of Flaxseed Oil Omega-3 Fatty Acids Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association. 2018;126(4):222-8.
44.
Mirfatahi M, Tabibi H, Nasrollahi A, Hedayati M. Effects of Flaxseed Oil on Serum Lipids and Lipoproteins in Hemodialysis Patients: a Randomized Controlled Trial. Iranian J Kidney Dis. 2016;10(6):405–12.
45.
Kontogianni MD, Vlassopoulos A, Gatzieva A, Farmaki AE, Katsiougiannis S, Panagiotakos DB, et al. Flaxseed oil does not affect inflammatory markers and lipid profile compared to olive oil, in young, healthy, normal weight adults. Metabolism: clinical and experimental. 2013;62(5):686-93.
46.
Edel AL, Patenaude AF, Richard MN, Dibrov E, Austria JA, Aukema HM, et al. The effect of flaxseed dose on circulating concentrations of alpha-linolenic acid and secoisolariciresinol diglucoside derived enterolignans in young, healthy adults. Eur J Nutr. 2016;55(2):651–63.PubMedCrossRef
47.
Akiyama S, Katsumata S, Suzuki K, Ishimi Y, Wu J, Uehara M. Dietary hesperidin exerts hypoglycemic and hypolipidemic effects in streptozotocin-induced marginal type 1 diabetic rats. J Clin Biochem Nutr. 2010;46(1):87–92.PubMedCrossRef
48.
Li C, Schluesener H. Health-promoting effects of the citrus flavanone hesperidin. Crit Rev Food Sci Nutr. 2017;57(3):613–31.PubMedCrossRef
49.
Mohammadi-Sartang M, Sohrabi Z, Barati-Boldaji R, Raeisi-Dehkordi H, Mazloom Z. Flaxseed supplementation on glucose control and insulin sensitivity: a systematic review and meta-analysis of 25 randomized, placebo-controlled trials. Nutr Rev. 2018;76(2):125–39.PubMedCrossRef
50.
Albert BB, Derraik JG, Brennan CM, Biggs JB, Smith GC, Garg ML, et al. Higher omega-3 index is associated with increased insulin sensitivity and more favourable metabolic profile in middle-aged overweight men. Scientific Rep. 2014;4:6697.CrossRef
51.
González-Périz A, Horrillo R, Ferré N, Gronert K, Dong B, Morán-Salvador E, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by ω-3 fatty acids: a role for resolvins and protectins. FASEB J. 2009;23(6):1946–57.PubMedPubMedCentralCrossRef
52.
Wien M, Rajaram S, Oda K, Sabaté J. Decreasing the linoleic acid to α-linolenic acid diet ratio increases eicosapentaenoic acid in erythrocytes in adults. Lipids. 2010;45(8):683–92.PubMedCrossRef
53.
Kuo S-M. The interplay between fiber and the intestinal microbiome in the inflammatory response. Advances Nutr. 2013;4(1):16–28.CrossRef
54.
Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99.PubMedCrossRef
55.
Sun Q, Wedick NM, Tworoger SS, Pan A, Townsend MK, Cassidy A, et al. Urinary Excretion of Select Dietary Polyphenol Metabolites Is Associated with a Lower Risk of Type 2 Diabetes in Proximate but Not Remote Follow-Up in a Prospective Investigation in 2 Cohorts of US Women–3. J Nutr. 2015;145(6):1280–8.PubMedPubMedCentralCrossRef
56.
Mulero J, Bernabé J, Cerdá B, García-Viguera C, Moreno DA, Albaladejo MD, et al. Variations on cardiovascular risk factors in metabolic syndrome after consume of a citrus-based juice. Clin Nutr. 2012;31(3):372–7.PubMedCrossRef
57.
Ghanim H, Sia CL, Upadhyay M, Korzeniewski K, Viswanathan P, Abuaysheh S, et al. Orange juice neutralizes the proinflammatory effect of a high-fat, high-carbohydrate meal and prevents endotoxin increase and Toll-like receptor expression–. Am J Clin Nutri. 2010;91(4):940–9.CrossRef
58.
Medina-Remón A, Casas R, Tressserra-Rimbau A, Ros E, Martínez-González MA, Fitó M, et al. Polyphenol intake from a Mediterranean diet decreases inflammatory biomarkers related to atherosclerosis: a substudy of the PREDIMED trial. Br J Clin Pharmacol. 2017;83(1):114–28.PubMedCrossRef
59.
Medina-Remón A, Tresserra-Rimbau A, Pons A, Tur JA, Martorell M, Ros E, et al. Effects of total dietary polyphenols on plasma nitric oxide and blood pressure in a high cardiovascular risk cohort. The PREDIMED randomized trial. Nutrition, Metabolism and Cardiovascular Diseases. 2015;25(1):60-7.
60.
Ursoniu S, Sahebkar A, Andrica F, Serban C, Banach M. Effects of flaxseed supplements on blood pressure: a systematic review and meta-analysis of controlled clinical trial. Clin Nutr. 2016;35(3):615–25.PubMedCrossRef
61.
Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J, et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet. 2001;358(9299):2130–1.PubMedCrossRef
62.
Prasad K. Secoisolariciresinol diglucoside (SDG) isolated from flaxseed, an alternative to ACE inhibitors in the treatment of hypertension. The International journal of angiology: official publication of the International College of Angiology, Inc. 2013;22(4):235.
63.
Caligiuri SP, Edel AL, Aliani M, Pierce GN. Flaxseed for hypertension: implications for blood pressure regulation. Curr Hypertens Rep. 2014;16(12):499.PubMedCrossRef
64.
Austria JA, Richard MN, Chahine MN, Edel AL, Malcolmson LJ, Dupasquier CM, et al. Bioavailability of alpha-linolenic acid in subjects after ingestion of three different forms of flaxseed. J Am Coll Nutr. 2008;27(2):214–21.PubMedCrossRef
65.
Kuijsten A, Arts IC, van’t Veer P, Hollman PC. The relative bioavailability of enterolignans in humans is enhanced by milling and crushing of flaxseed. The Journal of nutrition. 2005;135(12):2812-6.
66.
Yari Z, Rahimlou M, Poustchi H, Hekmatdoost A. Flaxseed supplementation in metabolic syndrome management: a pilot randomized, open-labeled, controlled study. Phytotherapy Res. 2016;30(8):1339–44.CrossRef
67.
Homayouni F, Haidari F, Hedayati M, Zakerkish M, Ahmadi K. Blood pressure lowering and anti-inflammatory effects of hesperidin in type 2 diabetes; a randomized double-blind controlled clinical trial. Phytotherapy Res. 2018;32(6):1073–9.CrossRef
68.
Klein S, Allison DB, Heymsfield SB, Kelley DE, Leibel RL, Nonas C, et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping America’s health: association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Obesity. 2007;15(5):1061–7.PubMedCrossRef
69.
Yari Z, Rahimlou M, Eslamparast T, Ebrahimi-Daryani N, Poustchi H, Hekmatdoost A. Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study. Int J Food Sci Nutr. 2016;67(4):461–9.PubMedCrossRef
70.
Mohammadi‐Sartang M, Mazloom Z, Raeisi‐Dehkordi H, Barati‐Boldaji R, Bellissimo N, Totosy de Zepetnek J. The effect of flaxseed supplementation on body weight and body composition: a systematic review and meta‐analysis of 45 randomized placebo‐controlled trials. Obesity Reviews. 2017;18(9):1096-107.
71.
Garaulet M, Hernández-Morante J, Tébar F, Zamora S. Anthropometric indexes for visceral fat estimation in overweight/obese women attending to age and menopausal status. J Physiol Biochemistry. 2006;62(4):245–52.CrossRef
72.
Buckley JD, Howe P. Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. Obes Rev. 2009;10(6):648–59.PubMedCrossRef
73.
Buckley JD, Howe PR. Long-chain omega-3 polyunsaturated fatty acids may be beneficial for reducing obesity—a review. Nutrients. 2010;2(12):1212–30.PubMedPubMedCentralCrossRef
74.
Setchell K, Adlercreutz H. Mammalian Lignans and Phytooestrogens Recent Studies on their Formation, Metabolism and Biological Role in Health and. Role of the gut flora in toxicity and cancer. 1988;315.
75.
Morisset A-S, Lemieux S, Veilleux A, Bergeron J, Weisnagel SJ, Tchernof A. Impact of a lignan-rich diet on adiposity and insulin sensitivity in post-menopausal women. Br J Nutr. 2009;102(2):195–200.PubMedCrossRef
76.
Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD. Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Advances Nutr. 2014;5(4):404–17.CrossRef
77.
Andriantsitohaina R, Auger C, Chataigneau T, Étienne-Selloum N, Li H, Martínez MC, et al. Molecular mechanisms of the cardiovascular protective effects of polyphenols. Br J Nutr. 2012;108(9):1532–49.PubMedCrossRef
Metadata
Title
Combination therapy of flaxseed and hesperidin enhances the effectiveness of lifestyle modification in cardiovascular risk control in prediabetes: a randomized controlled trial
Authors
Zahra Yari
Zahra Naser-Nakhaee
Elahe Karimi‐Shahrbabak
Makan Cheraghpour
Mehdi Hedayati
Seyede Marjan Mohaghegh
Shahrzad Ommi
Azita Hekmatdoost
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2021
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-020-00619-y

Other articles of this Issue 1/2021

Diabetology & Metabolic Syndrome 1/2021 Go to the issue

Research

LncRNA KCNQ1OT1 promotes the development of diabetic nephropathy by regulating miR-93-5p/ROCK2 axis

Research

Impact of prediabetes on long-term cardiovascular outcomes in patients with myocardial infarction with nonobstructive coronary arteries

Research

Association between fasting insulin and C-reactive protein among adults without diabetes using a two-part model: NHANES 2005–2010

Research

Genome-wide association analysis of metabolic syndrome quantitative traits in the GENNID multiethnic family study

Research

Metabolic control and hypoglycaemia in people with type 1 diabetes: insulin pump therapy vs. intensified insulin therapy in an unselected cohort in routine care

Research

Diagnostic significance of serum PP4R1 and its predictive value for the development of chronic complications in patients with type 2 diabetes mellitus

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits